Zempia® (E-101 Solution)

About Exoxemis

Exoxemis is a private, clinical-stage biotech developing Zempia®, a novel topical antiseptic based on the enzyme Myeloperoxidase (MPO). Its platform is designed to kill a broad spectrum of pathogens, including antibiotic-resistant bacteria, while uniquely inactivating bacterial endotoxins to potentially prevent sepsis. The company has completed a Phase III safety trial but has not yet received FDA approval, positioning it as a pre-revenue entity with a significant but high-risk opportunity in wound care and infection prevention.

Therapeutic Areas